Suppr超能文献

用于复发性阿弗他口炎的药物传递系统的演变。

Evolution of Drug Delivery Systems for Recurrent Aphthous Stomatitis.

机构信息

Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Padjadjaran University, Sumedang, Jatinangor, 45363, Indonesia.

School of Pharmacy Muhammadiyah Cirebon, Cirebon, Kedawung, 45153, Indonesia.

出版信息

Drug Des Devel Ther. 2021 Sep 27;15:4071-4089. doi: 10.2147/DDDT.S328371. eCollection 2021.

Abstract

Recurrent aphthous stomatitis (RAS) is a disease marked by painful oral lesions on the buccal and labial mucosa or tongue. Drug delivery systems (DDS) for RAS include topical forms that manage wound healing, cover the ulcer, and relieve the associated pain. DDS targeting the oral mucosa face a major challenge, especially the short residence times in the mouth due to the effect of "saliva wash-out", which continually removes the drug. The objective of this review is to study the development of preparation forms and delivery systems of various types and preparations that have been used for RAS management from 1965 until February 2020. There are 20 types of DDS for RAS which were discussed in 62 articles. The preparations were classified into 4 preparation forms: liquid, semi-solid, solid, and miscellaneous. In addition, the ultimate DDS for RAS preparations is the semi-solid forms (41.94%), which include 5 types of DDS are gel, paste, patch, cream, and ointment. This preparation was developed into new preparation form (11.29%), such as adhesive alginates, dentifrice, OraDisc, membranes, bioresorbable plates, pellicles, and gelosomes. Generally, the mucosal drug delivery system is the method of choice in RAS treatment because the ulcer is commonly located in the oral mucosa. In conclusion, these preparations are designed to improve drug delivery and drug activity for the treatment of RAS ulcers. Moreover, almost all of these DDS are topical preparations that use various types of mucoadhesive polymers to increase both residence time in the oral mucosa and pain relief in RAS treatment.

摘要

复发性阿弗他溃疡(RAS)是一种以颊黏膜和唇黏膜或舌上疼痛性口腔损伤为特征的疾病。RAS 的药物输送系统(DDS)包括管理伤口愈合、覆盖溃疡和缓解相关疼痛的局部形式。针对口腔黏膜的 DDS 面临着重大挑战,尤其是由于“唾液冲洗”的影响,口腔内的停留时间很短,这会不断清除药物。本综述的目的是研究从 1965 年到 2020 年 2 月用于 RAS 管理的各种类型和制剂的制剂形式和输送系统的发展。有 20 种用于 RAS 的 DDS 在 62 篇文章中进行了讨论。制剂被分为 4 种制剂形式:液体、半固体、固体和杂项。此外,RAS 制剂的最终 DDS 是半固体形式(41.94%),其中包括 5 种 DDS,即凝胶、糊剂、贴剂、乳膏和软膏。这种制剂被开发成新的制剂形式(11.29%),如粘性海藻酸盐、牙膏、OraDisc、膜、可生物降解的盘子、薄膜和凝胶体。一般来说,黏膜药物输送系统是 RAS 治疗的首选方法,因为溃疡通常位于口腔黏膜上。总之,这些制剂旨在改善药物输送和药物活性,以治疗 RAS 溃疡。此外,几乎所有这些 DDS 都是局部制剂,使用各种类型的黏膜黏附聚合物来增加药物在口腔黏膜中的停留时间,并缓解 RAS 治疗中的疼痛。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e3bb/8489189/fd257a0e80bc/DDDT-15-4071-g0001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验